Clinical & Scientific

A new wave of advanced cancer drugs is set to upend the market. As the EGFR inhibitor space surges towards $16B, we analyze the strategies behind the disruption.

A new precision drug, ART5803, is offering hope for a devastating brain disorder. Arialys Therapeutics is fast-tracking its development with key clinical trials.

A new study offers hope for MS by promoting nerve repair, but the real story is the validation of a versatile stem cell platform for a new era of medicine.

As 250 million people await a drug for lymphatic diseases, Celltaxis appoints a new CEO to drive its promising inflammation-targeting therapy toward the finish line.

Akeso's new breast cancer trial is more than a clinical step; it's a key move in a bold strategy to dominate next-gen cancer therapy and capture a lucrative market.

A breakthrough publication identifies a novel protein, LanCL1, as a key target for neuropathic pain, validating a new class of drugs for millions of sufferers.

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

Kymera Therapeutics reports promising data for KT-621, a first-in-class oral drug that removes a key inflammatory protein, not just block it.

Elixiron's enrupatinib shows promise in targeting neuroinflammation, with early data suggesting cognitive benefits and a new biomarker-guided path for therapy.

With a record-breaking IPO and over $1.2 billion raised this year, Parabilis Medicines is attacking diseases once thought untouchable. But can its Helicon platform deliver?

A key clinical trial completion in Japan signals a major shift in prostate cancer care, heralding the arrival of advanced PSMA-targeted theranostics.

A new deal brings a breakthrough blood cancer therapy, Zemcelpro®, closer to Canada. But for patients with few options, the 2028 timeline is a stark reminder of the gap between innovation and access.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.

Osisko Development's new high-grade gold intercepts at its Cariboo project aren't just a find; they're a strategic move to optimize a major new mine.

A novel TYK2 inhibitor that can enter the central nervous system has begun human trials, signaling a new frontier for treating diseases like MS and lupus.

New long-term data for masitinib shows a near doubling of 5-year survival for ALS patients, with many maintaining quality of life. Is this the turning point?

A new clinical trial for a twice-yearly COPD injection could disrupt a multi-billion dollar market, offering hope to millions and validating a novel biotech strategy.

Fredonia Mining advances its flagship gold project while consolidating a key Argentine district, a bold strategy to build a regional powerhouse next to giants.

Promising early data for obesity drug DA-1726 shows rapid weight loss, while vanoglipel demonstrates powerful synergy in MASH and diabetes combination therapies.

With a new CMO known for getting drugs approved, Protego Biopharma is betting big on its novel approach to treating a devastating rare disease.